The objective of the study was to test the use of a new atherectomy device to prepare severely calcified lesions. It was an observational, prospective, multicenter study that included 443 patients from 49 sites with a 30-day follow-up. The lesion was classified as severely calcified, as fluoroscopy showed the presence of calcium on both sides<a href="https://solaci.org/en/2015/06/24/orbit-ii-new-atherectomy-device/" title="Read more" >...</a>
Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis. The study was divided into two parts: the first one aimed at comparing, in the acute phase and the medium term, the result of provisional bifurcation stenting technique with sirolimus-eluting stent vs everolimus-eluting stent (both guided by IVUS); the<a href="https://solaci.org/en/2015/06/24/j-reverse-sirolimus-eluting-vs-everolimus-eluting-stent-in-bifurcation-lesions/" title="Read more" >...</a>
The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained unanswered: What is the utility of starting the infusion during the ambulance journey? Is it possible to reduce the risk of acute thrombosis by extending bivalirudin infusion or<a href="https://solaci.org/en/2015/06/24/euromax-bivalirudin-during-transport-to-primary-angioplasty/" title="Read more" >...</a>
The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was a combination of mortality, myocardial infarction, stent thrombosis in the resistance group (few responders) versus non-resistant (responders) to the thienopyridines. 1445 patients were included of which 22% were considered few responders. There<a href="https://solaci.org/en/2015/06/24/giant-evaluation-of-the-genetic-profile-of-cyp2c19-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>
The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined<a href="https://solaci.org/en/2015/06/24/savor-timi-53-saxagliptin-showed-no-cardiovascular-benefit/" title="Read more" >...</a>
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/current-hemodialysis-patients-show-similar-results-for-sirolimus-eluting-and-paclitaxel/" title="Read more" >...</a>
Only 16 per cent of patients suffering a myocardial infarction call 911 for help, stated the experts of the Semicyuc: the Spanish Medical Society of ICU (Sociedad Española de Medicina Intensiva y Unidades Coronarias), at the ARIAM study presentation. This study branched out of a three month registry of 2,051 MI patients. From these data<a href="https://solaci.org/en/2015/06/01/the-ambulance-is-the-best-way-to-get-to-the-hospital-in-case-of-an-infraction/" title="Read more" >...</a>
Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe<a href="https://solaci.org/en/2015/05/20/total-trial-the-best-on-manual-thrombectomy-in-ami-patients/" title="Read more" >...</a>
Original title: Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. The DAPT Study. Reference: Robert W. Yeh et al. J Am Coll Cardiol. 2015, online before print. The risks and benefits of prolonged antiplatelet therapy after PCI could be different in patients presenting with AMI compared to<a href="https://solaci.org/en/2015/04/21/risks-and-benefits-of-extending-dual-antiplatelet-therapy-in-patients-with-and-without-mi/" title="Read more" >...</a>
Título original: Long-Term Survival Benefit of Revascularization Compared UIT Medical Therapy in Practice UIT Coronary Chronic Total Occlusion and Well-Developed Collateral Circulation. Reference: Woo Jin Jan, el at. J Am Coll Cardiol Interv 2015;8:271-9 Multiple studies have shown the benefit of chronic total occlusion (CTO) revascularization, but for patients presenting Rentrop 3 grade collateral circulation (CC), such benefit<a href="https://solaci.org/en/2015/03/24/cto-revascularization-is-beneficial/" title="Read more" >...</a>